Lexaria Bioscience Reports Biodistribution Study Results, Sees Growth in GLP-1 Agonist Space

Lexaria Bioscience Corporation has reported data from its rodent biodistribution study and closed a $4.0 million capital raise. The company is working on multiple GLP-1 trials and has launched five human studies to evaluate the DehydraTECH formulation for GLP-1 agonists. Lexaria's data has shown reduced side effects and comparable glucose reduction compared to existing injectable drugs. The company seeks to attract a major player in the industry to recognize the value of an oral version of these injectable drugs.